Ocrelizumab (Ocrevus) Update

MS Ireland welcome the decision made by the HSE to reimburse Ocrelizumab or Ocrevus for people living with relapsing MS, including those with relapsing forms of secondary progressive MS. We are disappointed that this decision has not been extended to those with primary progressive MS. Ocrelizumab, which is administered via intravenous infusion every 6 months, is the only medication currently licensed for those living with relapsing and primary progressive forms of MS.

Ava Battles, Chief Executive of MS Ireland stated “This is an important milestone for people in Ireland living with relapsing-remitting MS. At MS Ireland, we advocate for improved services and access to treatments and the public availability of this drug is a huge step in the right direction. However, access to treatment remains a pivotal issue and we continue to campaign for better treatments for MS, including for those with primary progressive MS who continue to have an unmet treatment need.”

MS Ireland would like to thank all those who have engaged with our advocacy and lobbying efforts concerning the reimbursement of this medication so far. We will continue to advocate on this issue to make this medication available to all those who would benefit from it.